DMA Share Price

Open 0.28 Change Price %
High 0.28 1 Day 0.00 0.00
Low 0.28 1 Week -0.04 -12.50
Close 0.28 1 Month -0.02 -6.67
Volume 126500 1 Year -0.02 -6.67
52 Week High 0.40
52 Week Low 0.14
DMA Important Levels
Resistance 2 0.28
Resistance 1 0.28
Pivot 0.28
Support 1 0.28
Support 2 0.28
CVE Canada Most Active Stocks
PRY 0.02 0.00%
PRY 0.02 0.00%
PRY 0.02 0.00%
PRY 0.02 0.00%
COD 0.07 0.00%
COD 0.07 0.00%
COD 0.07 0.00%
DVN 0.17 0.00%
DVN 0.17 0.00%
DVN 0.17 0.00%
More..
CVE Canada Top Gainers Stocks
CAT 0.02 100.00%
CAT 0.02 100.00%
CAT 0.02 100.00%
CAT 0.02 100.00%
CAT 0.02 100.00%
BVQ 0.02 100.00%
XOP 0.02 100.00%
DDX 0.50 100.00%
AAT 0.02 100.00%
AAT 0.02 100.00%
More..
CVE Canada Top Losers Stocks
NUK 0.02 -50.00%
FEM 0.02 -50.00%
FEM 0.02 -50.00%
FEM 0.02 -50.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
BG 0.02 -33.33%
More..

Diamedica Inc (CVE: DMA)

DMA Technical Analysis 2
As on 23rd Jun 2017 DMA Share Price closed @ 0.28 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.24 & Strong Sell for SHORT-TERM with Stoploss of 0.32 we also expect STOCK to react on Following IMPORTANT LEVELS.
DMA Target for June
1st Target up-side 0.36
2nd Target up-side 0.4
3rd Target up-side 0.45
1st Target down-side 0.22
2nd Target down-side 0.18
3rd Target down-side 0.13
DMA Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.diamedica.com
DMA Address
DMA
One Carlson Parkway
Suite 124
Minneapolis, MN 55447
United States
Phone: 763-270-0603
DMA Latest News
Interactive Technical Analysis Chart Diamedica Inc ( DMA CVE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Diamedica Inc
DMA Business Profile
DiaMedica Inc., a development stage biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of diabetes and related diseases. The company’s lead clinical stage compound is DM199, a recombinant human protein known as rhKLK1, which is under phase I/II clinical trials for the treatment of Type 1 and Type 2 diabetes and associated complications. It is also developing DM204, a monoclonal antibody that is in preclinical development for the treatment of Type 2 diabetes; and DMDx, a chronic kidney disease assay to detect levels of the tissue kallikrein-1 protein in urine and to predict the rate of kidney disease progression. The company was formerly known as Diabex Inc. and changed its name to DiaMedica Inc. in February 2001. DiaMedica Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.